Search filters

List of works by Tony Reid

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

scientific article

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

scientific article published on 26 May 2016

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

scientific article published on 23 July 2018

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors

scientific article published in 2022

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

scientific article

COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making

scientific article published on 19 August 2020

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

scientific article

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

scientific article published on 19 September 2016

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19

scientific article published on 07 July 2020

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

scientific article published on 20 July 2017

Episensitization: Defying Time's Arrow

scientific article published on 11 June 2015

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients

scientific article published on 01 November 2019

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

scientific article

Going viral: a review of replication-selective oncolytic adenoviruses

scientific article (publication date: 21 August 2015)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

scientific article published on January 2016

Just eat it: A review of CD47 and SIRP-α antagonism

scientific article published on 30 May 2020

Locally advanced rectal cancer: The past, present, and future

scientific article published on 21 February 2020

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

scientific article

No patient left behind: The promise of immune priming with epigenetic agents

scientific article published on 30 August 2017

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

scientific article published on 24 May 2016

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

scientific article published on 28 January 2016

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

scientific article published on 11 September 2019

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

scientific article

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

scientific article published on January 2016

RRx-001 protects against cisplatin-induced toxicities.

scientific article published on 17 April 2017

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

scientific article

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

scientific article published on 9 December 2016

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

scientific article published on 24 April 2020

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm

scientific article

Rewriting the epigenetic code for tumor resensitization: a review.

scientific article

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

scientific article published on 19 August 2015

TGF-beta: a master immune regulator

scientific article published on 12 April 2020

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

scientific article published in August 2015

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

scientific article published on 27 April 2017

The war on cancer: a military perspective

scientific article

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

scientific article

What's New in SCLC? A Review

scientific article published on 6 September 2017

Paulina is supported by:

About Paulina

Help